Tekturna (Aliskiren Hemifumarate) Patent Expiration, LOE Window & CMS Spending

Tekturna (Aliskiren Hemifumarate) by Lxo Ireland Designated Activity: FDA Orange Book LOE 2026-08-19, 1 AB generics, $928K 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLxo Ireland Designated Activity
FDA Application & PathwayN021985 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-08-19
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$928K
2024 Medicare Part D Spend$868K
2024 Medicaid Spend$60K
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 29.5% 2-yr change)